L. Kobori
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
L. Kobori has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Balázs Nemes
Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary
9 shared publications D Görög
5 shared publications- Imre Fehérvári
Transzplantációs és Sebészeti Klinika, Semmelweis Egyetem, Általános Orvostudományi Kar Budapest
5 shared publications A. Doros
3 shared publications- Anikó Smudla
Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary
3 shared publications - Eniko Sarvary
Semmelweis Medical University, Transplantation and Surgical Clinic, Budapest, Hungary
3 shared publications
Latest Publications
- 1 January 2016
- Published by Elsevier in Journal of Hepatology
- Vol. 64 (2) , S298
Liver Transplantation in Hungarian Wilson’S Disease Patients, 1998–2015
- 1 January 2016
- Published by Elsevier in Journal of Hepatology
- Vol. 64 (2) , S298
Liver Transplantation in Hungarian Wilson’S Disease Patients, 1998–2015
- 1 December 2013
- Published by Elsevier in Transplantation Proceedings
- Vol. 45 (10) , 3688-3690
Retransplantations in the Hungarian Liver Transplant Program
- 1 December 2013
- Published by Elsevier in Transplantation Proceedings
- Vol. 45 (10) , 3688-3690
Retransplantations in the Hungarian Liver Transplant Program
- 16 May 2013
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 51 (05) , A48
Acute liver failure in Hungarian Wilson disease patients
Background and Aims: Acute liver failure (ALF) is a rare form of Wilson disease (WD) developing mostly in young female patients. Use of chelating agents and supportive therapies including MARS (Molecular Adsorbent Recirculating System) in time may result in a remission in some cases making liver transplantation unnecessary. Patients and Methods: We analyzed data of 205 Wilson patients registered in the database of the 1st Department of Internal Medicine of Semmelweis University. We studied retrospectively the clinical data of 24 patients with acute liver failure. The diagnosis of WD was based on the international scoring system. The ALF patients were hospitalized mostly in the Saint Laszlo Hospital, the 1st Department of Internal Medicine and the Department of Transplantation and Surgery of Semmelweis University. The ALF diagnosis corresponded to King's College criteria. Results: 12% (24/205) of the patients had acute liver failure as first manifestation of WD. F/M = 20/4, the mean age was 18 years. Nine patients died before liver transplantation. Three out of eight transplanted patients died (1 of acute rejection, 1 of chronic rejection and 1 of sepsis). Seven patients survived without transplantation. One of them had MARS treatment as bridging therapy. The de Ritis quotient (AST/ALT ratio) was significantly higher, the alkaline phosphatase level was significantly lower than in non-ALF WD patients (p < 0,001). 18 out of 24 ALF patients had Coombs-negative haemolysis. The H1069Q mutation was less frequent in patients with acute liver failure. Remarkably, most of the female patients developed ALF within four years after menarche. Conclusion: Corresponding with international data 12% of Hungarian Wilson patients had acute liver failure as the first manifestation of the disease. If ALF develops in a young adult the diagnosis of Wilson disease should be proposed. Although in many acute liver failure patients liver transplantation is the only life-saving method, in some cases the transplantation can be avoided by quick diagnosis and by early use of chelating drugs or bridging by MARS treatment.
- 16 May 2013
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 51 (05) , A48
Acute liver failure in Hungarian Wilson disease patients
Background and Aims: Acute liver failure (ALF) is a rare form of Wilson disease (WD) developing mostly in young female patients. Use of chelating agents and supportive therapies including MARS (Molecular Adsorbent Recirculating System) in time may result in a remission in some cases making liver transplantation unnecessary. Patients and Methods: We analyzed data of 205 Wilson patients registered in the database of the 1st Department of Internal Medicine of Semmelweis University. We studied retrospectively the clinical data of 24 patients with acute liver failure. The diagnosis of WD was based on the international scoring system. The ALF patients were hospitalized mostly in the Saint Laszlo Hospital, the 1st Department of Internal Medicine and the Department of Transplantation and Surgery of Semmelweis University. The ALF diagnosis corresponded to King's College criteria. Results: 12% (24/205) of the patients had acute liver failure as first manifestation of WD. F/M = 20/4, the mean age was 18 years. Nine patients died before liver transplantation. Three out of eight transplanted patients died (1 of acute rejection, 1 of chronic rejection and 1 of sepsis). Seven patients survived without transplantation. One of them had MARS treatment as bridging therapy. The de Ritis quotient (AST/ALT ratio) was significantly higher, the alkaline phosphatase level was significantly lower than in non-ALF WD patients (p < 0,001). 18 out of 24 ALF patients had Coombs-negative haemolysis. The H1069Q mutation was less frequent in patients with acute liver failure. Remarkably, most of the female patients developed ALF within four years after menarche. Conclusion: Corresponding with international data 12% of Hungarian Wilson patients had acute liver failure as the first manifestation of the disease. If ALF develops in a young adult the diagnosis of Wilson disease should be proposed. Although in many acute liver failure patients liver transplantation is the only life-saving method, in some cases the transplantation can be avoided by quick diagnosis and by early use of chelating drugs or bridging by MARS treatment.
- 6 May 2011
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 49 (05) , A58
Partial liver graft transplantation in childhood because of idiopathic fulminant liver failure benefits of the Mars treatment
Introduction: The mortality of fulminant liver failure is over 80%, the only possible choice for long term survival is liver transplantation. Because of the low number of donors partial liver transplantation (split, reduced-size) can be a solution with a survival rate over 85%. In 30% of the cases ethiology is unknown, however toxic and drug induced liver failure is rather common. By usage of the widely known amoxicillin-clavulic acid combination the incidence of hepatic laesion increases six times higher. Case report: Eight years old girl (25kg) recieved amoxicillin-clavulic acid treatment because of infection. Two weeks after (onset) icterus was detected and she was listed for high urgency liver transplantation. Accordin the King's College criteria. At the time of listing she presented hyperbilirubinaemia (SeBi 267mmol/l) significantly increased level of transaminases (SGOT 2061U/l, SGPT 1531U/l), coagulopathy (INR 3.94, prothrombin 18%) and encephalopathy. MARS treatment was used four times as bridging-therapy. Methods: Three weeks after listing a right split (right lobe) liver graft transplantation was done from a cadaveric donor (10years, 45kg) with CIT 510min and, WIT 37min). Ten days after transplantation she was transmitted to the pediatric department from the ICU without complications. Conclusion: Liver transplantation is still the best therapeutic option for patients with fulminant liver failure. MARS treatment is a benefitial bridging-therapy before liver transplantation in pediatric cases as well.
- 6 May 2011
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 49 (05) , A58
Partial liver graft transplantation in childhood because of idiopathic fulminant liver failure benefits of the Mars treatment
Introduction: The mortality of fulminant liver failure is over 80%, the only possible choice for long term survival is liver transplantation. Because of the low number of donors partial liver transplantation (split, reduced-size) can be a solution with a survival rate over 85%. In 30% of the cases ethiology is unknown, however toxic and drug induced liver failure is rather common. By usage of the widely known amoxicillin-clavulic acid combination the incidence of hepatic laesion increases six times higher. Case report: Eight years old girl (25kg) recieved amoxicillin-clavulic acid treatment because of infection. Two weeks after (onset) icterus was detected and she was listed for high urgency liver transplantation. Accordin the King's College criteria. At the time of listing she presented hyperbilirubinaemia (SeBi 267mmol/l) significantly increased level of transaminases (SGOT 2061U/l, SGPT 1531U/l), coagulopathy (INR 3.94, prothrombin 18%) and encephalopathy. MARS treatment was used four times as bridging-therapy. Methods: Three weeks after listing a right split (right lobe) liver graft transplantation was done from a cadaveric donor (10years, 45kg) with CIT 510min and, WIT 37min). Ten days after transplantation she was transmitted to the pediatric department from the ICU without complications. Conclusion: Liver transplantation is still the best therapeutic option for patients with fulminant liver failure. MARS treatment is a benefitial bridging-therapy before liver transplantation in pediatric cases as well.
- 6 May 2011
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 49 (05) , A43
Screening of drug metabolizing capacity of the liver using peripheral blood sample. CYP-phenotype, allele and genotype frequencies
Drug-metabolizing capacity of the liver or transplanted liver graft depends on levels and activities of cytochrome P450 enzymes (CYP). Liver injury increase the morbidity and mortality rate after liver surgery or transplantation. Inter-individual variations in CYP genes result in differences in drug metabolism. Metabolomic and transcriptomic tools were used for CYP-phenotyping, based on the fact that strong correlation exists between CYP enzyme activities in the liver and expression at mRNA level in leucocytes. For CYP-genotyping genomic DNA was extracted from the leukocytes or from the liver tissues of the donors and genotype analysis for single nucleotide polymorphism (SNPs) was performed by PCR. Phenotyping 100 liver donors, the incidence of transplanted poor metabolizer liver grafts was up to 37%. CYP gene expression in the donor leucocytes presented poor metabolism in 37% for CYP3A4 and CYP2C9, in 13% for CYP2C19. The incidence of these poor metabolizer livers was higher, up to 75% in males. Intermediate and extensive metabolizers were documented too. Biopsy showed drug toxicity in only 48%. Permanent 'poor metabolism' for CYP2C9, CYP2C19 and CYP3A5 was attempted to be estimated by CYP-genotyping of 102 liver donors. In this donor group, 13.7% carried one, and 0.98% carried two CYP2C9*2 mutated alleles, while 12.7% carried one, no donors carried two CYP2C9*3 mutated alleles. Furthermore, 33.3% of the donors were found to be heterozygous and 2% homozygous for the CYP2C19*2, while no CYP2C19*3 was detected, 10.78% carried one and all the others 89.22% carried two CYP3A5*3 mutated alleles. No homozygous wild types were detected for CYP3A5 gene. In summary, prospective non-invasive investigation of CYP status of the liver can be beneficial in clinical practice. Individual medication can improve the liver and kidney function, can reduce the level of encephalopathy with lower morbidity and mortality rate.
- 6 May 2011
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 49 (05) , A43
Screening of drug metabolizing capacity of the liver using peripheral blood sample. CYP-phenotype, allele and genotype frequencies
Drug-metabolizing capacity of the liver or transplanted liver graft depends on levels and activities of cytochrome P450 enzymes (CYP). Liver injury increase the morbidity and mortality rate after liver surgery or transplantation. Inter-individual variations in CYP genes result in differences in drug metabolism. Metabolomic and transcriptomic tools were used for CYP-phenotyping, based on the fact that strong correlation exists between CYP enzyme activities in the liver and expression at mRNA level in leucocytes. For CYP-genotyping genomic DNA was extracted from the leukocytes or from the liver tissues of the donors and genotype analysis for single nucleotide polymorphism (SNPs) was performed by PCR. Phenotyping 100 liver donors, the incidence of transplanted poor metabolizer liver grafts was up to 37%. CYP gene expression in the donor leucocytes presented poor metabolism in 37% for CYP3A4 and CYP2C9, in 13% for CYP2C19. The incidence of these poor metabolizer livers was higher, up to 75% in males. Intermediate and extensive metabolizers were documented too. Biopsy showed drug toxicity in only 48%. Permanent 'poor metabolism' for CYP2C9, CYP2C19 and CYP3A5 was attempted to be estimated by CYP-genotyping of 102 liver donors. In this donor group, 13.7% carried one, and 0.98% carried two CYP2C9*2 mutated alleles, while 12.7% carried one, no donors carried two CYP2C9*3 mutated alleles. Furthermore, 33.3% of the donors were found to be heterozygous and 2% homozygous for the CYP2C19*2, while no CYP2C19*3 was detected, 10.78% carried one and all the others 89.22% carried two CYP3A5*3 mutated alleles. No homozygous wild types were detected for CYP3A5 gene. In summary, prospective non-invasive investigation of CYP status of the liver can be beneficial in clinical practice. Individual medication can improve the liver and kidney function, can reduce the level of encephalopathy with lower morbidity and mortality rate.
- 1 May 2011
- Published by Elsevier in Transplantation Proceedings
- Vol. 43 (4) , 1275-1277
Volumetric Hemodynamic Changes and Postoperative Complications in Hypothermic Liver Transplanted Patients
- 1 May 2011
- Published by Elsevier in Transplantation Proceedings
- Vol. 43 (4) , 1275-1277
Volumetric Hemodynamic Changes and Postoperative Complications in Hypothermic Liver Transplanted Patients
- 1 July 2010
- Published by Elsevier in Transplantation Proceedings
- Vol. 42 (6) , 2312-2314
Results and Complications after Living Related Kidney Transplantation in Hungary: 30 Years' Experience
- 1 July 2010
- Published by Elsevier in Transplantation Proceedings
- Vol. 42 (6) , 2312-2314
Results and Complications after Living Related Kidney Transplantation in Hungary: 30 Years' Experience
- 27 July 2008
- Published by Wolters Kluwer Health in Transplantation
- Vol. 86 (2S) , 419
MTOR INHIBITORS IN LIVER TRANSPLANTATION - THE BUDAPEST PRACTICE
- 27 July 2008
- Published by Wolters Kluwer Health in Transplantation
- Vol. 86 (2S) , 419
MTOR INHIBITORS IN LIVER TRANSPLANTATION - THE BUDAPEST PRACTICE
- 1 May 2008
- Published by Elsevier in Transplantation Proceedings
- Vol. 40 (4) , 1216-1217
Epidural Anesthesia? No of Course
- 1 May 2008
- Published by Elsevier in Transplantation Proceedings
- Vol. 40 (4) , 1216-1217
Epidural Anesthesia? No of Course
- 4 May 2005
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 43 (05) , 33
Liver transplantation for chronic liver diseases – ten years experience in Budapest
Aims: The liver transplant program in Budapest was started ten years ago and 216 transplantations – ten in the first year, 43 in the last year – were performed in 202 patients. Aim of the study was to evaluate our results achieved in the treatment of chronic non-malignant liver diseases that are the main indication of transplantation. Patients and methods: Data of patients grafted for chronic liver diseases were retrospectively reviewed. Beside demographic and clinical characteristics three-months mortality and morbidity including primary nonfunction, hepatic artery thrombosis, intraabdominal bleeding, biliary leakage, acute renal failure required renal replacement therapy, acute rejection, and infection with clinical signs, furthermore one year patient survival were examined in two periods: 1995–2002 and 2003–2004. Five year patient survival was calculated and compared in different groups of patients selected by indication of transplantation. Results: Of 170 patients with chronic liver disease 110 underwent liver transplantation between 1995–2002, the rest received liver graft in 2003–2004. There were 88 men and 82 women with mean age of 40 years. Distribution of patients by underlying disease was the following: cirrhosis on Hepatitis C virus (HCV, n=66), cholestatic liver disease (n=36), alcoholic liver disease (ALD, n=35) and others (n=33). The three-months mortality and morbidity were 26% and 80% in the first period and 5% and 68% in 2003–2004. The difference between mortality rates is highly significant (pConclusions: After learning curve the three-months mortality rate and the incidence of hepatic artery thrombosis have significantly lowered resulted in improved (91%) one year patient survival. According the late outcome cholestatic and alcoholic liver diseases were the best indication of transplantation. The significantly lower five year patient survival for HCV cirrhosis was due to the recurrence of hepatitis.
- 4 May 2005
- Published by Georg Thieme Verlag KG in Zeitschrift für Gastroenterologie
- Vol. 43 (05) , 33
Liver transplantation for chronic liver diseases – ten years experience in Budapest
Aims: The liver transplant program in Budapest was started ten years ago and 216 transplantations – ten in the first year, 43 in the last year – were performed in 202 patients. Aim of the study was to evaluate our results achieved in the treatment of chronic non-malignant liver diseases that are the main indication of transplantation. Patients and methods: Data of patients grafted for chronic liver diseases were retrospectively reviewed. Beside demographic and clinical characteristics three-months mortality and morbidity including primary nonfunction, hepatic artery thrombosis, intraabdominal bleeding, biliary leakage, acute renal failure required renal replacement therapy, acute rejection, and infection with clinical signs, furthermore one year patient survival were examined in two periods: 1995–2002 and 2003–2004. Five year patient survival was calculated and compared in different groups of patients selected by indication of transplantation. Results: Of 170 patients with chronic liver disease 110 underwent liver transplantation between 1995–2002, the rest received liver graft in 2003–2004. There were 88 men and 82 women with mean age of 40 years. Distribution of patients by underlying disease was the following: cirrhosis on Hepatitis C virus (HCV, n=66), cholestatic liver disease (n=36), alcoholic liver disease (ALD, n=35) and others (n=33). The three-months mortality and morbidity were 26% and 80% in the first period and 5% and 68% in 2003–2004. The difference between mortality rates is highly significant (pConclusions: After learning curve the three-months mortality rate and the incidence of hepatic artery thrombosis have significantly lowered resulted in improved (91%) one year patient survival. According the late outcome cholestatic and alcoholic liver diseases were the best indication of transplantation. The significantly lower five year patient survival for HCV cirrhosis was due to the recurrence of hepatitis.